Table 2.
Radiological response according to RECIST1.1 and survival.
| LEN + NIVO n = 16 | LEN + PEM n = 13 | All patients n = 29 | |
|---|---|---|---|
| Best response | |||
| CR | 1 (6.3%) | 0 | 1 (3.4%) |
| PR | 5 (31.2%) | 1 (7.7%) | 6 (20.7%) |
| SD | 4 (25%) | 8 (61.5%) | 12 (41.4%) |
| PD | 4 (25%) | 4 (30.8%) | 8 (27.6%) |
| Not evaluable | 2 (12.5%) | 0 | 2 (6.9) |
| ORR (CR+PR) | 6 (37.5%) | 1 (7.7%) | 7 (24.1%) |
| DCR (CR+PR+SD) | 10 (62.5%) | 9 (69.2%) | 19 (65.5%) |
| TTP, median (95% CI) | 7 (95% CI 0.39-13.61) | – | 7 (95% CI 3.44-10.56) |
| DOR (range, months) | 7 (3-11) | – | 7 (3-11) |
| 6-months PFS rate | 43.8% | 49.2% | 43.5% |
| 12-months PFS rate | 30.0% | 49.2% | 31.8% |
| 6-months OS rate | 62.5% | 51.3% | 62.6% |
| 12-months OS rate | 52.1% | 51.3% | 53.7% |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; TTP, time to progression; DOR, duration of response; PFS, progression-free survival; OS, over survival.